

Name	Company	Characteristics	Approved Uses	FDA Aprv
Hyaluronic Acid (HA) Fillers				
BELOTERO Balance® (+)	Merz Aesthetics®	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 22.5 mg/mL.	For injection into the mid to deep dermis for the correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). For improvement of the infraorbital hollow (IOH) in adults over the age of 21 (9/2023).	Nov-2011
BELOTERO Volume® (+)	Merz Aesthetics®	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 26 mg/mL	For injection in the midface to restore volume and correct midface contour deficiencies, including adding fullness to the cheeks, in adults 22 years of age or older.	May-2026
BELOTERO Intense® (+)	Merz Aesthetics®	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 25.5 mg/mL	For injection into and around the lips to temporarily add volume and improve lip fullness in adults over the age of 21.	July-2026
EVOLYSSE™ FORM	Evolus	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 22 mg/mL.	For dermal and subdermal injection to correct moderate to severe dynamic facial wrinkles and folds (such as nasolabial folds) in adults 22 years and older.	Feb-2025
EVOLYSSE™ SMOOTH	Evolus	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL.	For dermal and subdermal injection to correct moderate to severe dynamic facial wrinkles and folds (such as nasolabial folds) in adults 22 years and older.	Feb-2025
Juvederm® Ultra, Ultra XC, Ultra Plus, Ultra Plus XC	Allergan Aesthetics, an AbbVie Company	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 24 mg/mL XC products contain 0.3% lidocaine.	All Ultra products are indicated for injection into the mid-to-deep dermis for correction of moderate to severe wrinkles and folds (such as nasolabial folds). Ultra XC is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21 (9/2015).	Jun-2006
Juvéderm® Volbella® XC	Allergan Aesthetics, an AbbVie Company	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 15 mg/mL.	For injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21. For improvement of infraorbital hollows in adults over the age of 21. (5/2021)	May-2016
Juvéderm® Vollure® XC	Allergan Aesthetics, an AbbVie Company	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 17.5 mg/mL.	For injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.	Mar-2017

Name	Company	Characteristics	Approved Uses	FDA Aprv
Hyaluronic Acid (HA) Fillers				
Juvéderm® Voluma® XC	Allergan Aesthetics, an AbbVie Company	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL.	For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21. For supraperiosteal injection to augment the temple region to improve moderate to severe temple hollowing in adults over the age of 21 (6/2023).	Oct-2013
Juvéderm® Volux® XC	Allergan Aesthetics, an AbbVie Company	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 25 mg/mL.	For subcutaneous and/or supraperiosteal injection for improvement in jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.	Jul-2022
SKINVIVE by Juvéderm®	Allergan Aesthetics, an AbbVie Company	Bacteria-based HA Filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 12.5 mg/mL.	For intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21. For the improvement of neck appearance in adults over the age of 21 (6/2026).	May-2023
Restylane® /Restylane®- L	Galderma	Bacteria-based HA filler, cross-linked with BDDE. Total HA concentration: 20 mg/mL. Particle size range: 330-430 µm. Restylane-L contains 0.3% lidocaine.	For injection into the mid to deep dermis for the correction of moderate to severe facial wrinkles and folds (such as the nasolabial folds). Restylane®- L is also indicated for submucosal implantation for lip augmentation in patients over the age of 21 (10/2011).	Dec-2003
Restylane® Contour	Galderma	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL.	For use in cheek augmentation and for the correction of midface contour deficiencies in adults over the age of 21.	Jun-2021
Restylane® Defyne	Galderma	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL.	For injection into the mid-to-deep dermis for correction of moderate to severe, deep facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21. For augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion in patients over the age of 21.	Dec-2016

Name	Company	Characteristics	Approved Uses	FDA Aprv
Hyaluronic Acid (HA) Fillers				
Restylane® Eyelight	Galderma	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL.	For the improvement of infraorbital hollowing in patients over the age of 21.	May-2023
Restylane® Kysse	Galderma	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL. This product has a moderate lifting capacity.	For injection into the lips for lip augmentation and the correction of upper perioral rhytids in patients over the age of 21.	May-2020
Restylane® Lyft	Galderma	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL.	For implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds. For subcutaneous to supraperiosteal implantation for cheek augmentation and correction of age-related midface contour deficiencies in patients over the age of 21. For injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over the age of 21 (5/2018). For augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion (11/2025).	Feb-2010
Restylane® Refyne	Galderma	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL. Restylane® Refyne is less crosslinked than Restylane® Defyne.	For injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21.	Dec-2016
Restylane® Silk	Galderma	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA Concentration: 20 mg/mL. Particle size range: 50–220 µm.	For submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.	Jun-2014
Revanesse® Lips™	Prollenium® Medical Aesthetics	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 22-28 mg/mL.	For submucosal implantation for lip augmentation in patients 22 years of age or older.	Aug-2018

Name	Company	Characteristics	Approved Uses	FDA Aprv
Hyaluronic Acid (HA) Fillers				
Revanesse®	Prollenium®	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 25 mg/mL.	For injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds in adults 22 years of age or older.	Aug-2017
RHA® 2 Mepi	Revance	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% mepivacaine. Total HA concentration: 23 mg/g.	For injection in the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older.	Oct-2017
RHA® 3 Mepi	Revance	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% mepivacaine. Total HA concentration: 23 mg/g.	For injection in the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. For injection into the vermilion body, vermilion border and oral commissure to achieve lip augmentation and lip fullness in adults aged 22 or older (10/2023).	Oct-2017
RHA® 4 Dynamic	Revance	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% mepivacaine. Total HA concentration: 23 mg/g.	For injection into the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. For cheek augmentation and/or correction of age-related midface contour deficiencies in adults aged 22 or older (09/2025).	Oct-2017
RHA Redensity™	Revance	Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% mepivacaine. Total HA concentration: 15 mg/mL.	For injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids, in adults aged 22 years or older.	Dec-2021

Name	Company	Characteristics	Approved Uses	FDA Aprv
Biostimulatory Fillers				
Radiesse® / Radiesse®(+)	Merz Aesthetics®	Calcium hydroxylapatite (CaHA) microspheres suspended in an aqueous gel carrier. Radiesse®(+) contains 0.3% lidocaine.	Radiesse®/ Radiesse®(+): For subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Radiesse®: For hand augmentation to correct volume loss in the dorsum of the hands and for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. Radiesse®(+): For deep injection (subdermal and/or supraperiosteal) for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over the age of 21. Radiesse® Injectable Implant diluted 1:2 with 0.9% sterile saline for injections is intended for the treatment of moderate and severe décolleté wrinkles (04/2026).	Dec-2006
Sculptra®	Galderma	Microparticles of poly-L-lactic acid (PLLA) - lyophilized product.	For correction of shallow to deep nasolabial fold deficiencies and other facial wrinkles for use in immune-competent subjects. For correction of fine lines and wrinkles in the cheek region for use in immune-competent patients. For restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.	Nov-2021
Permanent Fillers				
Bellafill®	Suneva Medical	Polymethylmethacrylate microspheres (PMMA) suspended in 3.5% denatured bovine collagen, mixed with 0.3% lidocaine. Skin test required.	For the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheeks of patients over the age of 21.	Oct-2006
Neuromodulators				
BOTOX® Cosmetic (onabotulinumtoxinA)	Allergan Aesthetics, an AbbVie Company	Purified protein produced by the Clostridium botulinum bacterium; onabotulinumtoxinA. Single use vial containing 50 or 100 units.	For the temporary improvement in the appearance of moderate to severe glabella lines associated with corrugator and/or procerus muscle activity in adult patients. For the temporary improvement in the appearance of moderate to severe lateral canthal lines associated with orbicularis oculi activity (9/2013). For moderate to severe forehead lines associated with frontalis muscle activity (10/2017). For moderate to severe platysma bands associated with platysma muscle activity (10/2024).	Apr-2002

Name	Company	Characteristics	Approved Uses	FDA Aprv
Neuromodulators				
Daxxify™	Revance	Derived from fermentation of Clostridium botulinum and available as a single use vial containing 50 or 100 units.	For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.	Sep-2022
Dysport™ (abobotulinumtoxinA)	Galderma	Purified protein produced by the Clostridium botulinum bacterium; abobotulinumtoxinA. Single use vial containing 300 or 500 units.	For the temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients < 65 years of age.	Apr-2009
Jeuveau™ (prabotulinum-toxinA-xvfs)	Evolus	Derived from fermentation of Clostridium botulinum and available as a single use vial containing 100 units.	For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.	Feb-2019
Letybo® (letibotulinumtoxinA)	Hugel	Derived from a newly isolated Clostridium botulinum strain CBFC26 isolated from canned soybeans (2001) and available in a single use vial in 50 or 100 units.	For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. For moderate to severe horizontal forehead lines associated with muscle activity. For moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity.	Mar-2024
Xeomin®	Merz Aesthetics®	Purified protein produced by the Clostridium botulinum bacterium; incobotulinumtoxinA. Single use vial containing 50 or 100 units.	For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.	Jul-2011